Combination therapy for advanced lung cancer after immunotherapy
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of three drugs for people with advanced non-small cell lung cancer that has grown despite previous immunotherapy. The goal is to see if adding these drugs can help control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- You have advanced non-small cell lung cancer that has progressed after treatment with a PD-1/PD-L1 inhibitor (like pembrolizumab or nivolumab).
- You have not previously received anti-angiogenic therapy (drugs that block blood vessel growth to tumors).
- Your tumor does not have certain gene changes (EGFR, ALK, ROS1, or RET).
- You are in generally good health (able to care for yourself) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs — sintilimab (an immunotherapy) and anlotinib (a targeted therapy) — for people with small cell lung cancer that has worsened after previous immunotherapy. The goal is to see if this combination can help control the cancer when standard treatments have stopped working.
This trial is testing a new combination of treatments, including an immune drug (sintilimab) and a cholesterol-lowering drug (tafolecimab), along with chemotherapy, for people with advanced lung cancer that no longer responds to standard immunotherapy.
This trial tests a combination of an immunotherapy drug (sintilimab) with chemotherapy to shrink advanced lung cancer that cannot be removed with surgery. The goal is to see if the cancer becomes operable after treatment and to improve outcomes.
This trial tests a combination of two drugs, tislelizumab and anlotinib, for people with advanced non-small cell lung cancer that has progressed after initial immunotherapy. The goal is to see if this new combination can help control the cancer.
This trial tests a new combination of two drugs (Adibelimab and Famitinib) plus chemotherapy for people with advanced non-small cell lung cancer whose previous immunotherapy (PD-1 inhibitor) has stopped working. The goal is to see if this new combination can help control the cancer when the first treatment fails.
This trial tests a combination of an immunotherapy drug (sintilimab) with chemotherapy and an anti-angiogenesis drug (rh-endostatin) for people with advanced or recurrent squamous non-small cell lung cancer. The goal is to see if this combination can shrink tumors and improve outcomes.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.